Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Sanchez-Perez

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Nature Biotechnology|August 22, 2019
Rescuing imperfect antigens for immuno-oncologySelena J Lorrey, Luis Sanchez-Perez, Peter E Fecci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2019
Brain Tumor Microenvironment and Host State: Implications for ImmunotherapyWilliam Tomaszewski, Luis Sanchez-Perez, Thomas F Gajewski, et al.
Journal for Immunotherapy of Cancer|April 23, 2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeuticsElias J Sayour, Luis Sanchez-Perez, Catherine Flores, et al.
Oncoimmunology|January 23, 2015
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrenceLaura A Johnson, Luis Sanchez-Perez, Carter M Suryadevara, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2008
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activityNicole Asprodites, Liqin Zheng, Degui Geng, et al.
Biomaterials Science|May 27, 2020
Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopesYaoying Wu, Sean H Kelly, Luis Sanchez-Perez, et al.
Current Drug Discovery Technologies|February 21, 2012
Immunotherapy with tumor vaccines for the treatment of malignant gliomasDivya Ajay, Luis Sanchez-Perez, Bryan D Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2005
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapyMichael Gough, Marka Crittenden, Uma Thanarajasingam, et al.
Oncoimmunology|January 30, 2014
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibodyBryan D Choi, Patrick C Gedeon, Luis Sanchez-Perez, et al.
Expert Opinion on Biological Therapy|October 4, 2018
Promising vaccines for treating glioblastomaAdam M Swartz, Steven H Shen, Miguel A Salgado, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Nature Biotechnology|August 22, 2019
Rescuing imperfect antigens for immuno-oncologySelena J Lorrey, Luis Sanchez-Perez, Peter E Fecci
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 27, 2019
Brain Tumor Microenvironment and Host State: Implications for ImmunotherapyWilliam Tomaszewski, Luis Sanchez-Perez, Thomas F Gajewski, et al.
Journal for Immunotherapy of Cancer|April 23, 2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeuticsElias J Sayour, Luis Sanchez-Perez, Catherine Flores, et al.
Oncoimmunology|January 23, 2015
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrenceLaura A Johnson, Luis Sanchez-Perez, Carter M Suryadevara, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 1, 2008
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activityNicole Asprodites, Liqin Zheng, Degui Geng, et al.
Biomaterials Science|May 27, 2020
Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopesYaoying Wu, Sean H Kelly, Luis Sanchez-Perez, et al.
Current Drug Discovery Technologies|February 21, 2012
Immunotherapy with tumor vaccines for the treatment of malignant gliomasDivya Ajay, Luis Sanchez-Perez, Bryan D Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2005
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapyMichael Gough, Marka Crittenden, Uma Thanarajasingam, et al.
Oncoimmunology|January 30, 2014
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibodyBryan D Choi, Patrick C Gedeon, Luis Sanchez-Perez, et al.
Expert Opinion on Biological Therapy|October 4, 2018
Promising vaccines for treating glioblastomaAdam M Swartz, Steven H Shen, Miguel A Salgado, et al.
Pageof 7